Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

187 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chimeric antigen receptor-T cell therapy shows similar efficacy and toxicity in patients with diffuse large B-cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study.
Berning P, Shumilov E, Maulhardt M, Boyadzhiev H, Kerkhoff A, Call S, Reicherts C, Saidy AO, Aydilek E, Hoffmann M, Novak U, Daskalakis M, Schmitz N, Stelljes M, Wulf G, Bacher U, Lenz G, Pabst T. Berning P, et al. Among authors: novak u. Hemasphere. 2024 Mar 20;8(3):e54. doi: 10.1002/hem3.54. eCollection 2024 Mar. Hemasphere. 2024. PMID: 38510993 Free PMC article.
Analysis of autophagy in DLBCL reveals subtype-specific differences and the preferential targeting of ULK1 inhibition in GCB-DLBCL provides a rationale as a new therapeutic approach.
Mandhair HK, Radpour R, Westerhuis M, Banz Y, Humbert M, Arambasic M, Dengjel J, Davies A, Tschan MP, Novak U. Mandhair HK, et al. Among authors: novak u. Leukemia. 2024 Feb;38(2):424-429. doi: 10.1038/s41375-024-02147-4. Epub 2024 Jan 23. Leukemia. 2024. PMID: 38263431 Free PMC article. No abstract available.
Biorefining Twin Transition: Digitalisation for Bio-based Chemicals/Materials - Discovery, Design and Optimisation.
Žula M, Grilc M, Kostyniuk A, Tofani G, Jasiukaitytė-Grojzdek E, Ročnik Kozmelj T, Kumar Chowdari R, Lavrič Ž, Teržan J, Hočevar B, Jakob A, Rakić E, Pomeroy B, Cajnko MM, A Vicente F, Marinič D, Oberlintner A, Novak U, Benedetto Tiz D, Huš M, Likozar B. Žula M, et al. Among authors: novak u. Chimia (Aarau). 2023 Dec 20;77(12):816-826. doi: 10.2533/chimia.2023.816. Chimia (Aarau). 2023. PMID: 38131404 Free article.
Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997-2021.
Passweg JR, Baldomero H, Ansari M, Arber C, Chalandon Y, Daskalakis M, Diepold M, Diesch-Furlanetto T, Duchosal MA, Gerull S, Güngör T, Heim D, Hitz F, Holbro A, Masouridi-Levrat S, Nair G, Novak U, Pabst T, Renner C, Stussi G, Schneidawind D, Schanz U, Wannesson L, Halter JP; Swiss Blood Stem Cell Transplantation Group (SBST). Passweg JR, et al. Among authors: novak u. Hematol Oncol. 2024 Jan;42(1):e3241. doi: 10.1002/hon.3241. Epub 2023 Dec 6. Hematol Oncol. 2024. PMID: 38058031
R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial.
Chamuleau MED, Stenner F, Chitu DA, Novak U, Minnema MC, Geerts P, Stevens WBC, Zenz T, van Imhoff GW, Wu KL, Demandt AMP, Kersten MJ, Terpstra WE, Tick LW, Deeren D, Van Den Neste E, Gregor M, Veelken H, Böhmer LH, Caspar CB, Mutsaers P, Refos JM, Sewsaran R, Fu L, Seefat RL, Uyl-de Groot CA, Dirnhofer S, Van Den Brand M, de Jong D, Nijland M, Lugtenburg P. Chamuleau MED, et al. Among authors: novak u. Lancet Haematol. 2023 Dec;10(12):e966-e975. doi: 10.1016/S2352-3026(23)00279-X. Epub 2023 Oct 31. Lancet Haematol. 2023. PMID: 37922925 Clinical Trial.
Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party.
Penack O, Peczynski C, Koenecke C, Polge E, Sanderson R, Yakoub-Agha I, Fegueux N, Daskalakis M, Collin M, Dreger P, Kröger N, Schanz U, Bloor A, Ganser A, Besley C, Wulf GG, Novak U, Moiseev I, Schoemans H, Basak GW, Chabannon C, Sureda A, Glass B, Peric Z. Penack O, et al. Among authors: novak u. Front Immunol. 2023 Sep 27;14:1252811. doi: 10.3389/fimmu.2023.1252811. eCollection 2023. Front Immunol. 2023. PMID: 37828980 Free PMC article.
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13).
Novak U, Fehr M, Schär S, Dreyling M, Schmidt C, Derenzini E, Zander T, Hess G, Mey U, Ferrero S, Mach N, Boccomini C, Böttcher S, Voegeli M, Cairoli A, Ivanova VS, Menter T, Dirnhofer S, Scheibe B, Gadient S, Eckhardt K, Zucca E, Driessen C, Renner C. Novak U, et al. EClinicalMedicine. 2023 Sep 22;64:102221. doi: 10.1016/j.eclinm.2023.102221. eCollection 2023 Oct. EClinicalMedicine. 2023. PMID: 37781158 Free PMC article.
187 results